Vancouver, BC – The Michael Smith Foundation for Health Research (MSFHR) has issued a call for applications for a study to evaluate the long-term effectiveness of the GardasilTM vaccine. The vaccine provides protection against four strains of the human papilloma virus implicated in the development of genital warts and cervical cancer.
With support from British Columbia’s provincial government and several other provinces and territories, MSFHR will fund a 15-year clinical trial to determine the long-term effectiveness of a two-dose human papilloma virus (HPV) vaccine for adolescent girls age 9-13.
Up to $2.2 million is available for the study, which must be pan-provincial/territorial in scope. Letters of Intent (LOI) are due by January 31, 2010.
More information is available at www.msfhr.org/news/news_blog/2010/12/HPV